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Aging is characterized by a progressive loss of the ability of the organism to cope with 
stressors and to repair tissue damage. As a result, chronic diseases, including car-
diovascular disease, increase their prevalence with aging, underlining the existence of 
common mechanisms that lead to frailty and age-related diseases. In this frame, the 
progressive decline of the homeostatic and reparative function of primitive cells has been 
hypothesized to play a major role in the evolution of cardiac pathology to heart failure. 
Although initially it was believed that reactive oxygen species (ROS) were produced in 
an unregulated manner as a byproduct of cellular metabolism, causing macromolecular 
damage and aging, accumulating evidence indicate the major role played by redox 
signaling in physiology. Aim of this review is to critically revise evidence linking ROS to 
cell senescence and aging and to provide evidence of the primary role played by redox 
signaling, with a particular emphasis on the multifunctional protein APE1/Ref in stem 
cell biology. Finally, we will discuss evidence supporting the role of redox signaling in 
cardiovascular cells.
Keywords: aging, heart failure, reactive oxygen species, redox signaling, stem cells, APe/Ref-1, metabolism
iNTRODUCTiON
In humans, chronological aging is associated with both a progressive decline of the ability of the 
organism to maintain homeostasis and with a gradual reduction of the ability to cope with stressors 
and to repair tissue damage. This progressive functional decline eventually leads to a condition named 
frailty that is characterized by an increased vulnerability to serious adverse clinical outcome triggered 
by minor stressor events (1). Frailty is nowadays considered to be the result of loss of homeostatic 
control in several physiological systems (e.g., endocrine, hematopoietic, skeletal muscle, nervous, 
and cardiovascular systems) and has been associated with altered energetics (2). This condition may 
occur even in the absence of specific pathologic conditions. However, chronic diseases, such as heart 
failure, type II diabetes, and chronic obstructive lung disease, increase their prevalence with aging 
and increase the risk for frailty [reviewed by Ref. (3)]. To understand the common mechanisms 
that lead to frailty and age-related diseases is a challenge that may unveil strategies for rejuvenation 
and that could increase the health-span. According to current theories, aging would result from the 
interaction between environmental stresses and error-preventing or error-correcting systems that 
are comprised within a finite organism, where the majority of energy is allocated to maintain the 
reproductive system at the expenses of the soma [discussed in Ref. (4)].
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Among age-related diseases, cardiovascular disease has an 
impressive prevalence, considering that the remaining lifetime 
risk for cardiovascular disease is about 50% at the age of 40 (5). 
Consistently, the pathophysiologic modifications that are 
observed in aging hearts and arteries interact with alterations 
that characterize atherosclerosis progression, concurring to the 
development of age-associated heart failure. This latter is due to 
a combined diastolic and systolic dysfunction, caused by cardiac 
hypertrophy, replacement fibrosis, and myocardial ischemia, 
even in the absence of atherosclerotic coronary disease (6).
(STeM) CeLL SeNeSCeNCe iN 
CARDiOvASCULAR AGiNG AND HeART 
FAiLURe
Morphometric data acquired in the early 1990s suggested that 
the number of left ventricle cardiomyocytes declines progressively 
with aging (7). Consistently, investigators have documented that 
although cardiomyocyte turnover occurs postnatally, the rate of 
cardiomyocyte renewal declines as age advances (8). Intriguingly, 
while the same investigators have recently suggested that the 
total number of cardiomyocytes residing in the left ventricle does 
not change with aging (9), evidence of myocyte death has been 
shown to occur both in male primates (10) and in humans. In 
these latter, cardiac troponin T levels increase with aging and can 
predict cardiovascular events and death in the general popula-
tion (11, 12). This finding is thought to be the consequence of 
the age-related reduction of expression or activity of proteins 
that are involved in cardioprotection, a condition that eventually 
leads to an increased susceptibility of cardiac myocytes to injury 
[reviewed in Ref. (13)].
To understand the mechanisms leading to heart failure, we 
and other authors hypothesized that the reduced cardiomyocyte 
turnover observed in aging was a consequence of the reduced 
cardiac growth reserve. Although, as anticipated, postnatal 
cardiomyocyte proliferation has been widely accepted, a 
heated debate surrounds the origin of these mature cells. As we 
discussed in a recent review (14), several independent groups 
have shown that undifferentiated, primitive cells reside in mam-
malian hearts and are involved in cardioprotection against heart 
failure, possibly generating new myocytes (15). Conversely, dif-
ferent lines of evidence obtained in animal models of heart failure 
(e.g., doxorubicin-induced cardiomyopathy, diabetic cardio-
myopathy) and in humans (i.e., patients affected by heart failure 
of ischemic and non-ischemic nature) indicate that senescent 
and dysfunctional cardiac resident stem/progenitor cells (CS/PC) 
accumulate as a consequence of cardiac pathology (16–20). 
Furthermore, with organism aging, senescent primitive and dif-
ferentiated cells accumulate in mammalian hearts (21, 22).
Although the concept of cellular senescence was introduced 
more than 50 years ago, postulating that the irreversible growth 
arrest observed in cultures of diploid human cells after a fixed 
number of cell replications was one of the main mechanisms of 
organism aging, the debate around this programmed cellular 
behavior is still ongoing (23). Specifically, in relatively recent 
years, it has been shown that cell senescence may exert positive 
effects, by promoting tissue healing after injury and protecting 
young organisms from cancer (24). However, in line with the 
antagonistic pleiotropy theory of aging, these beneficial effects 
exerted by cell senescence in young animals may be also respon-
sible for the occurrence of functional impairment and age-related 
pathologies (25). Consistently, “rejuvenation” strategies aimed 
at reducing the frequency of senescent cells in the organism or 
designed to modulate those pathways whose activation status is 
altered in cell senescence can restore cardiac function in aged and 
failing hearts (19, 22).
Finally, we should emphasize that, while it has been postulated 
that reactive oxygen species (ROS) play a primary role in the 
development of cell senescence (26, 27), the molecular mecha-
nisms responsible for the development and evolution of cellular 
senescence are still a matter of intense research.
iNvOLveMeNT OF ROS iN AGiNG AND 
CeLL SeNeSCeNCe
In this regard, for many years it was believed that ROS were 
produced in an unregulated manner as a byproduct of cellular 
metabolism. Moreover, their ability to cause damage to macro-
molecules (e.g., proteins and nucleic acids) was thought to be 
responsible for organism aging (also known as the mitochondrial 
free radical theory of aging -MFRTA-) (28). Consistently, several 
pieces of evidence have shown an age-dependent decrease in 
mitochondrial integrity, and a parallel increase in the level of 
oxidized DNA (including the mitochondrial one) (29, 30). These 
alterations have led to the formulation of “the vicious cycle 
hypothesis of mitochondrial ROS generation,” according to which 
the mitochondrial production of ROS would damage mitochon-
drial DNA (mtDNA) and lead to mitochondrial dysfunction, thus 
increasing ROS generation. However, discordant results have 
been obtained in more recent years, which have either supported 
or refuted the increased production of mitochondrial ROS with 
aging (31–33). Most importantly, the experimental modulation 
of intracellular ROS levels led to contradictory effects on animal 
lifespan. Among the studies that supported the free radical 
theory of aging, we should acknowledge that: the deletion of 
p66shc, an isoform of the proteins encoded by the SHC1 gene that 
modulates mitochondrial ROS generation in response to stress 
activated p53 (34), determined the extension of lifespan in mice 
(35). Additionally, by targeting human catalase, an enzyme that 
is normally localized within the peroxisome, to either the nucleus 
or the mitochondria of transgenic mice, authors described a 
significant increase of median life span only in the latter group 
of animals (36). However, a series of experimental studies 
have provided strong evidence against the core of the MFRTA. 
Among these, the unsuccessful or even deleterious effects of the 
exogenous supplementation of antioxidants that was observed 
in clinical trials (37) or the genetic manipulation of the levels of 
manganese-dependent superoxide dismutase (SOD2, the major 
mitochondrial superoxide scavenger) that failed to show effects 
on mouse life span (38, 39).
These seemingly contradictory results can be reconciled if we 
consider that ROS have a dual nature, as recently reviewed in 
Ref. (40). In fact, on top of their ability to damage in non-specific 
FiGURe 1 | Oxidative folding and endoplasmic reticulum (eR) stress. (A) Following protein synthesis, the activity of chaperones (such as BiP) and ER 
enzymes is coordinated to reach a correct protein folding. In this process, protein disulfide isomerase (PDI) oxidizes critical cysteine residues in nascent proteins to 
facilitate correct folding, resulting in PDI reduction. PDIs are subsequently oxidized [mainly by endoplasmic reticulum oxidoreductin 1 (ERO1)], thus generating H2O2, 
which is buffered by cytoplasmic glutathione. (B) In conditions associated with ER stress (e.g., increased protein synthesis or altered ER redox balance),  
unfolded proteins accumulate in the ER lumen. Part of these are sent to ER-associated degradation, part sequester BiP, thus activating the unfolded protein 
response (UPR).
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fashion biological molecules, ROS (specifically O2
i− and H2O2) can 
exert useful and beneficial effects, by regulating signaling path-
ways. Although the modalities of reduction-oxidation (redox)-
dependent signaling have been only partially delineated (see 
discussion later), according to current models, ROS generation is 
highly regulated and redox-dependent transduction pathways are 
compartmentalized. Therefore, oxidative stress would arise from 
the loss of this architecture (41). Given these premises, we will 
discuss how the sources of oxidants and the mechanism of redox 
signaling are related to cell senescence.
Oxidant Sources that May Be Altered in 
Cell Senescence
Although in most cell types mitochondria are considered to be 
the major producers of ROS, other modalities of oxidant genera-
tion are also in place. We will briefly discuss them, pointing out 
their involvement in cellular senescence processes.
The endoplasmic reticulum (ER) is an organelle responsible for 
lipid, steroid and protein biosynthetic processes, protein post-
translational modifications (e.g., glycosylation and disulfide bond 
formation), protein folding, and Ca2+ storage (42). ER-localized 
enzymes and chaperones (most prominently BiP) work together 
to facilitate protein folding. Intriguingly, oxidative folding 
(i.e., the process of correct protein folding and disulfide bond 
formation, Figure 1), which requires the transfer of one electron 
from protein disulfide isomerase (PDI) to endoplasmic reticulum 
oxidoreductin-1 and molecular oxygen, provides a link between 
protein synthesis and ROS generation (43). Furthermore, a 
correct balance between reduced and oxidized glutathione is 
required to maintain ER oxidoreductases in a reduced state and 
to buffer the ROS produced by the oxidative folding process (44). 
However, when proteins fail to fold, they are sent to ER-associated 
degradation (ERAD) via the ubiquitin proteasome system (45). 
Importantly, certain conditions, including an altered balance of 
reducing and oxidative agents (46, 47) or an increased rate of 
protein synthesis that saturates the folding capacity of the ER, 
eventually lead to the accumulation of unfolded proteins in the ER 
lumen, causing ER stress (45). Prolonged ER stress both activates 
the unfolded protein response (UPR), which either restores cell 
homeostasis or induces apoptosis, and promotes ROS generation 
(45). In line, UPR and ROS can activate apoptosis signal regulat-
ing kinase 1 (ASK1), an oxidative stress responsive kinase, that 
leads to the activation of p38 mitogen-activated protein kinase 
(MAPK) and c-Jun-N terminal kinase (JNK) (48). Another 
possible source of ER-derived ROS are proteins of the reduced 
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 
(NOX) family, whose members form protein complexes that cata-
lyze the transfer of electrons from NADPH to molecular oxygen 
to produce superoxide anions in different physiologic and patho-
logic conditions (Table  1). Importantly, during ER stress both 
ER-localized NOX4 and plasma membrane localized NOX2 can 
activate cell death in a ROS-dependent fashion (49, 50). A third 
crucial function of the ER, which may induce oxidative stress, is 
the electron transfer chain of the “microsomal monooxygenase” 
(MMO), a multi-enzymatic system localized in the ER of most 
animal tissues whose main function is to oxygenate hydropho-
bic exogenous (e.g., xenobiotics) and endogenous substrates 
(e.g., arachidonic acid, steroids) (51). Intriguingly, a large part 
of the reducing substrates are employed by eukaryotic P450 
enzymes to generate ROS, while the efficiency and coupling of 
P450 enzymes are regulated by cofactors, such as cytochrome b5, 
or by post-translational modifications, such as phosphorylation 
(52). Finally, hormones (e.g., glucagon, glucocorticoids and thy-
roid hormones), cytokines (e.g., interferon and tumor necrosis 
factor), and apoptotic stimuli may modulate MMO-dependent 
ROS production (52, 53).
TABLe 1 | NADPH oxidase family members.
Family 
member




Host defense; growth factor and 
hormone (e.g., AngII) signaling.
(54–56)
NOX2 P47phox; p67phox; 
p40phox; Rac1; 
p22phox
Oxidative burst; ER-stress-induced 
apoptosis; AngII signaling.
(50, 57, 58)
NOX3 NOXO1; p22phox Development of otoconia crystals. (59)
NOX4 p22phox ER-stress-induced apoptosis. (49)
NOX5 Ca2+; 
phosphorylation
Spermatozoa motility; endothelial cell 
proliferation and capillary formation; 
smooth muscle cell proliferation and 
migration.
(60–62)
DUOX1 Ca2+ Thyroid hormonogenesis. (63)
DUOX2 Ca2+ Host defense; iodination of thyroid 
hormone.
(56, 64)
FiGURe 2 | Crosstalk between endoplasmic reticulum (eR) and mitochondria. In conditions of ER stress, PKR-like ER kinase (PERK) phosphorylates eIF2α 
which, in turn, reduces protein translation and promotes the expression of the transcription factor ATF4. This latter, subsequently promotes the transcription of 
Parkin, a protein that stimulates mitochondrial fission, mitochondrial autophagy, and the transfer of calcium from the ER to the mitochondria at the mitochondria-
associated membranes (MAM). Furthermore, a kinase independent function of PERK promotes the tethering of the ER to mitochondria at the MAM and the 
oxidation of cardiolipin.
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a transcription factor involved in the UPR response, increases the 
expression of Parkin, a ubiquitin ligase that regulates mitochon-
drial fission [see discussion below (66)], bioenergetics—by favor-
ing transients of Ca2+ transfer from ER to mitochondria (67)-, and 
mitophagy (68), while PERK (double stranded RNA-dependent 
protein kinase (PKR)-like ER kinase), another mediator of the 
UPR, is enriched at the mitochondria-associated ER membranes 
and favors the propagation of ROS from ER to the mitochondria 
(69). A major role in this cross-talk is played by Ca2+, which is 
mainly stored in the ER, where it is imported by the sarcoplasmic/
endoplasmic reticulum ATPase and is released via both the inosi-
tol 1,4,5-triphosphate receptor (IP3R) and the ryanodine receptor 
(RyR, in excitable cells as neurons and myocytes). Ca2+ is released 
from the ER during stress, enters mitochondria and increases both 
oxidative phosphorylation (70) and (possibly) ROS generation 
[critically reviewed in Ref. (71)]. Conversely, ROS themselves can 
alter calcium homeostasis by regulating IP3R (72) and RyR (73) 
function. Finally, recent evidences indicate that mitochondria 
do not exist permanently as single entities, but they rather form 
dynamic networks, exchanging proteins, lipids and mtDNA by 
fusion and fission cycles. Although mitochondrial fusion and 
fission regulate mitochondrial dynamics, it is unclear why do 
these processes happen. It has been postulated that mitochondrial 
Although mitochondria have been identified since many years 
as one of the major sources of ROS, it has been recognized only 
more recently that, as shown in Figure 2, in case of ER stress, a 
cross talk between ER and mitochondria promotes mitochondrial 
dysfunction [see (65) for a detailed review]. In this regard, ATF4, 
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fusion could dilute damaged mtDNA with wild type mtDNA, 
while fission could separate dysfunctional mitochondria to be 
sent to the autophagy/lysosomal pathway (74).
Cell senescence may affect the above-cited pathways at multiple 
levels. In this regard, p53 and mechanistic target of rapamycin 
(mTOR) signaling play a central role. mTOR, whose over-acti-
vation has been considered to act as a molecular switch between 
cell quiescence and senescence (75), overloads the ER, possibly 
activating the UPR. Although this latter activates autophagy and 
stimulates mitophagy (65), mTOR exerts opposing effects, inhib-
iting autophagy and lysosomal biogenesis (76), possibly leading 
to the accumulation of dysfunctional mitochondria. In line, with 
a systems biology approach, Dalle Pezze et al. recently demon-
strated that the dual inhibition of ROS and mTOR signaling was 
required to partially reduce senescence-induced mitochondrial 
dysfunction and DNA damage in early stages of irradiation-
induced cell senescence (27). Consistently, oncogenic RAS and 
oxidative stress activate NOX1 and NOX4, promoting autophagy 
and senescence, via p38 MAPK, p53, and p16INK4A pathway 
in a ROS-dependent fashion (77, 78). Finally, cell senescence 
depresses mitochondrial fusion and fission events, thus leading 
to the accumulation of dysfunctional mitochondria (27).
With specific reference to the cardiovascular system, mTOR 
activation may occur as a consequence of both increased glucose 
6 phosphate availability in overloaded hearts (79), and of the 
accumulation of branch chain amino acids, a condition that 
occurs with heart failure (80).
Mechanisms of Redox Signaling
With specific regard to the mechanisms of redox signaling, several 
models have been hypothesized, according to which ROS signal 
either directly by oxidizing (usually) crucial cysteine residues 
of signaling proteins or indirectly via either hydroperoxidation 
of peroxiredoxins (PRDX) or modulation of the thioredoxin 
(TRX) redox status [reviewed in Ref. (81)]. Protein tyrosine 
phosphatases (PTPs) are the best characterized and most studied 
redox regulated signaling proteins. PTP protein family includes 
classical tyrosine phosphatases and dual-specificity phosphatases 
(82). These latter comprise members that can dephosphorylate 
either phosphoserine and phosphothreonine residues or phos-
phatidylinositol (3,4,5)-triphosphate [catalyzed, this latter event, 
by phosphatase and tensin homolog (PTEN)] (83). When critical 
cysteine residues in the active site are oxidized, the phosphatase 
activity is inhibited, promoting kinase signaling. Sensitivity to spe-
cific oxidants (e.g., H2O2 vs. O2
i−) and restriction of oxidative events 
to cellular microdomains provides target specificity [see Ref. (84) 
for review]. More recently, it has been shown that the activity of 
protein kinases too may be modulated (both positively and nega-
tively) in a redox-dependent fashion. Specifically, this process was 
first described in Src and, subsequently, in many kinases that are 
involved in cardiovascular physiology and function, including Src 
family kinases, receptor tyrosine kinases (e.g., insulin receptor, 
epidermal growth factor and platelet derived growth factor recep-
tors), c-Abl, Akt2, cAMP- and cGMP-dependent protein kinases 
(i.e., PKA and PKG, respectively), ERK2, Jnk2, p38 MAPK, 
Ca2+/calmodulin-dependent protein kinase II (CaMKII), ataxia-
teleangectasia mutated protein kinase (ATM), and ASK1 (85).
To function in a reversible fashion, redox signaling requires, 
in analogy with phosphatases in protein kinase signaling, the 
existence of systems able to reduce oxidized targets. For example, 
critical cysteine residues can be oxidized to sulfenic, sulfinic, or 
sulfonic acid derivatives, whose reaction with neighboring amino 
acid residues can form intramolecular, reversible bonds, that can 
promote conformational changes of active sites and inhibition of 
the protein activity (84). To prevent or reverse these processes, 
the cell is equipped with antioxidant molecules (e.g., glutathione) 
and antioxidant enzymes, which show substrate specificity 
(e.g., superoxide dismutases reduce only superoxide, while catalase 
and PRDX only act on H2O2). Intriguingly, although initially con-
sidered only as ROS scavengers, these systems are now considered 
to act as sensors, involved in redox signal transduction. Among 
the most prominent antioxidant systems, we must acknowledge 
the TRX system, that catalyzes electron transfer from NADPH 
to TRX via thioredoxin reductase [extensively reviewed in 
Ref. (86)]. Proteins pertaining to the TRX family (e.g., TRX1, 
TRX2, glutaredoxins, PDIs, and quiescin-sulfhydryl oxidase), 
in turn, reduce substrate proteins—including other reductive 
enzymes (86). In addition, TRX proteins have been involved in 
the modulation of protein function by the covalent binding of NO 
to target cysteines (i.e., S-nitrosylation). More than a thousand 
proteins have been shown to be S-nitrosylated in vivo, many of 
which are involved in the pathogenesis of degenerative diseases 
(e.g., Parkin and Ryanodine Receptors) (87). Intriguingly, 
TRX1 can be nitrosylated on Cys73 by S-nitrosoglutathione, 
once a disulfide bond is formed between its Cys32 and Cys35 and 
the TRX1 disulfide reductase and denitrosylase activities are 
inhibited. In this condition, TRX1 can inhibit apoptosis pro-
moting the trans-S-nitrosylation of Caspase3 (88). This finding 
indicates that TRX1 can either promote trans-S-nitrosylation 
or de-nitrosylation, depending on the redox status of the cell. 
Consequently, the regulation of TRX reductase activity is crucial 
for modulating its different functions. Among the known regula-
tors of TRX reductase, we can include the transcription factor 
nuclear factor (erythroid-derived 2)-like 2 (Nrf2), selenium, and, 
most importantly for our discussion, caveolin 1, a structural com-
ponent of caveolae, whose expression is induced by p38 MAPK 
(89, 90). Intriguingly, we recently discussed the involvement of 
caveolin 1 in cardiac stem cell senescence (91). Among the reduc-
tive enzymes regulated by TRX, the PRDX family of reductive 
enzymes is responsible for scavenging H2O2 and are involved, 
together with TRX and interacting proteins, in regulating apop-
tosis via ASK1 and proliferation via PTEN (86). Furthermore, 
oxidation-reduction cycles of PRDX are nowadays considered to 
be a universal marker of circadian rhythm and provide a clue on 
the connection between the cellular redox state and the circadian 
clocks (92). Intriguingly, it has been shown that cell senescence 
impairs circadian rhythmicity and, conversely, that an impaired 
expression of clock genes is associated with aging, inducing cell 
senescence in a redox-dependent fashion (92, 93).
A special mention in our discussion should be given to 
the major role played by ROS in the regulation of autophagy. 
In line, redox signaling modulates the autophagic pathway at 
several levels. It may be briefly summarized that ROS induce 
autophagy, which, in turn, reduces the production of ROS. 
FiGURe 3 | APe1 redox chaperone activity. Schematic representation of 
APE1 redox chaperone activity. Cysteine residues located within the DNA 
binding domain or regulatory domain of transcription factors are maintained 
in a reduced state by APE1, involved in a redox cycle with reducing 
molecules as TRX. The detailed redox mechanism by which APE1 controls 
the activity of transcription factors needs further investigation. [Image 
modified, with permission from the copyright holder, from Tell et al. (114) Cell 
Mol Life Sci].
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Both peroxisome derived H2O2 and mitochondria derived O2
i− 
are involved in this process (94, 95). Importantly, a blockade 
of mitochondrial autophagy promotes the accumulation of 
damaged, ROS generating mitochondria. This event in turn 
triggers the activation of the nucleotide-binding oligomeriza-
tion domain, leucine-rich repeat and pyrin domain containing 
3 (NLRP3) inflammasome, thus promoting the release of 
cytokines that spread cell senescence and inflammation in a 
paracrine fashion (96).
Although lipids can be oxidized by lipoxygenases, cyclooxy-
genases, and cytochrome P450 to generate signaling molecules, 
ROS (e.g., hydroxyl radical—HO•− and hydroperoxyl—HO2
i−) 
produced in less controlled conditions may also cause peroxida-
tion of lipids containing carbon-carbon double bonds, such as 
polyunsaturated fatty acids (PUFA), generating lipid peroxyl 
radicals and hydroperoxides (97). Malondialdehyde (MDA) and 
4-hydroxynonenal (4-HNE) are among the best characterized 
secondary products of lipid peroxidation. MDA can be produced 
either by enzymatic processes during the metabolism of PUFA, 
such as the biosynthesis of thromboxane A2, or by non-enzymatic 
reactions (98). Intriguingly, recent data indicate that MDA, not 
only can promote intramolecular or intermolecular crosslinking, 
DNA damage or mutation (99), but can also act as a signaling 
molecule that regulates, for example, the glucose-stimulated 
insulin secretion in murine islets (100) or inhibit cardiac con-
tractility via p38 MAPK (101). 4-HNE as well may be produced 
during enzymatic metabolism (i.e., as a consequence of the action 
of arachidonate 15-lipoxygenase) or by non-enzymatic oxidation 
of ω-6 PUFA (102). The effects of this hydoxyalkenal have been 
extensively studied and reviewed (98). Specifically, 4-HNE has 
been shown to regulate stress responsive transcription factors 
(among which NRF2, NF-κB, and peroxisome-proliferator-
activated receptors) that modulate the expression of antioxidant 
proteins, inflammation, and metabolism; moreover, it may 
modulate the function of MAPK (e.g., p38 and JNK) and of 
protein-kinase C. Of particular interest for our discussion is the 
role played by 4-HNE in cell senescence, since it may inhibit the 
expression of the catalytic subunit of telomerase (hTERT) (103) 
and activate p53 (104).
Finally, ROS can oxidize nucleic acids. Whereas most of the 
attention has been dedicated to the study of nuclear and mtDNA 
oxidation, recent data indicate that, in many pathological condi-
tions (e.g., neurodegenerative diseases, atherosclerosis, and dia-
betes), RNA can be oxidized too (105–108). RNA oxidation stalls 
the translational machinery, thus reducing the rate of protein 
synthesis (109). Intriguingly, several reports indicate that RNA 
oxidation is not a random process, but affects genes involved in 
specific functions, such as: protein and ATP biosynthesis, electron 
transport chain, tricarboxylic acid cycle, glycolysis, protein fold-
ing and UPR, enzymatic anti-oxidation, and autophagy/lysosome 
pathway-mediated degradation (106, 107).
ReDOX SiGNALiNG AND APe1/ReF
As previously stated, beside their toxic effects, ROS play a 
critical role as signaling molecules, altering the cellular and 
extracellular redox state, in a broad variety of cellular processes as 
cellular proliferation and survival, DNA damage response and gene 
regulation. A large body of research demonstrates a general effect 
of oxidative stress on gene expression via direct modulation of 
transcription factors activity, regulation mediated by the redox 
state of thiol groups exposed by critic cysteine residues, located 
within the DNA binding domain of the transcription factors. 
At first, independent studies have identified APE1, the main 
AP-endonuclease of BER pathway of DNA lesions, as a factor 
able to stimulate the binding activity of several transcription 
factors through a redox-dependent mechanism (110). Since this 
first report, several transcription factors, both ubiquitous [e.g., 
NF-κB, Egr-1, p53, CREB, hypoxia inducible factor 1α (HIF-1α)] 
and tissue specific (e.g., TTF-1 and Pax proteins), with opposite 
effects on cell fate, have been reported to be modulated by 
APE1 (111). Interestingly, it is likely that APE1 could select, in 
response to specific stimuli, which transcription factors should 
be regulated, binding to them with different efficiencies. It has 
been proposed that APE1 might regulate the binding activity of 
transcription factors via regulation of the cysteine state, located 
in the DNA binding domain or domains critical for their activ-
ity, maintaining them in a reduced state by direct interaction 
(Figure 3) (112–114). Three possible mechanisms, not mutually 
exclusive, might explain the APE1 redox chaperone activity. In 
the so-called recruitment model, APE1 may facilitate the reduc-
tion of the transcription factors by bridging them to the reducing 
molecule (GSH or Trx). According to the conformational change 
model, instead, APE1 may induce a conformational change in the 
target factor, rendering accessible the cysteine residues otherwise 
buried in the structure. Finally, according to the oxidation barrier 
model, APE1 may stabilize the reduced state, preventing the oxi-
dation, via formation of hydrogen bond with thiol groups (113). 
The detailed molecular steps for the activation of the transcription 
7Cesselli et al. The Emerging Role of APE/Ref
Frontiers in Cardiovascular Medicine | www.frontiersin.org May 2017 | Volume 4 | Article 38
factors by APE remain to be largely investigated. Up to now, how-
ever, none of the APE1 cysteine residues has been found in a C-X-
X-C motif, common to most redox regulatory factors, such as 
TRX, which is implicated in the redox APE1 cascade by restoring 
APE1 in a reduced form (115). Several lines of evidence propose 
Cys65 as the redox-active site for APE1 (116, 117); however, the 
three-dimensional structure model demonstrates that none of 
the APE1 cysteine residues is localized in the right position and 
distance for forming a disulfide bond with Cys65, a prerequisite 
for resolving activity of redox factors. Moreover, both Cys65 and 
Cys93, residues identified as responsible for the redox regulation, 
are buried within the APE1 structure, being surface inaccessible, 
whose activities may be influenced by partial APE1 unfolding 
(118). Recently, Georgiadis and coworkers have proposed a new 
model based on current knowledge, suggesting that APE1 is a 
unique redox factor with properties distinct from those of other 
redox factors. In this model, (i) Cys65 acts as nucleophile for the 
reduction of the disulfide bond in the target factor, (ii) Cys93 
operates as resolving residue, and (iii) APE1 undergoes a signifi-
cant partial unfolding to expose a third cysteine residue, prob-
ably Cys99, to facilitate the redox reaction (118). Further works 
are needed to delineate the precise molecular mechanism of the 
reaction.
The localization of APE1 is predominantly nuclear, although 
the protein is also present within the mitochondrial compartment 
as essential component of the mtBER pathway (119). Notably, 
the mechanisms regulating APE1 intracellular trafficking are 
still largely unknown. In 2011, Li et  al. demonstrated that the 
APE1 mitochondrial localization signal resides within residues 
289–318 of the C-terminus, which are normally masked by the 
N-terminal domain. This suggests the necessity of specific and 
regulated mechanisms of protein unfolding–refolding to ensure 
proper APE1 localization. Additional studies identified residues 
Lys299 and Arg301 as critical residues for APE1 interaction with 
Tom20 and consequently for the mitochondrial translocation of 
the protein (120). Further advancement in the characterization 
of the mitochondrial residence of APE1 was brought about by 
our recent work, where we discovered a role for the redox-based 
MIA pathway to promote the mitochondrial translocation of 
APE1 (121). The Mitochondrial intermembrane space import and 
assembly protein 40 (Mia40) and augmenter of liver regeneration 
represent the central components of the MIA pathway; an import 
machinery that uses a redox system to drive cysteine-rich proteins 
into the mitochondrial compartment (122, 123). Recently, we 
demonstrated that human Mia40 is able to interact with and bind 
APE1 by forming a disulfide bridge between the residues Cys93 on 
APE1 and Cys55 on Mia40. Importantly, Cys53 and Cys55 consti-
tute the catalytic cysteine-proline-cysteine (CPC) motif of Mia40. 
Mutation of APE1 at Cys93 negatively affects the capacity of the 
protein to accumulate in an active form within the mitochondria 
leading to increased levels of mtDNA damage (121). The inner 
membrane complex responsible for the translocation of APE1 into 
the matrix compartment has still to be identified, as well as the role 
of APE1 within mitochondria has to be clarified. Back in 1995, 
Barzilay et al. hypothesized for the first time the existence of non-
canonical functions for APE1, suggesting a potential involvement 
of APE1 in the RNA metabolism and measuring its RNaseH-like 
activity (124). Only later, evidence of APE1 association with 
ribosomes in the cytoplasm of different cell types suggested that 
APE1 could also bind to RNA molecules in vivo. In addition to 
the direct interaction with RNA molecules, APE1 was also found 
to interact with other factors involved in RNA metabolism such 
as YB-1 and hnRNP-L. Altogether, these observations suggested 
a profound involvement of APE1 in the RNA metabolism, but 
until recently it was not clear what kind of activity APE1 could 
exert on RNA molecules (125). We first demonstrated that APE1 
has endonuclease activity not only on AP-site containing double-
stranded DNA but also on single-stranded DNA and RNA (125), 
suggesting a potential cleansing role for APE1 on abasic RNA. 
Unlike DNA molecules, RNA is mostly single stranded, with 
bases not protected by base pairing or by specific proteins. These 
features can result in increased susceptibility to oxidative insults. 
If let unrepaired, damage to RNA can lead to altered pairing, 
resulting in ribosomal dysfunction and erroneous translation thus 
significantly affecting the entire protein synthesis mechanism. 
Interestingly, oxidative damage to RNA molecules, with either 
coding (mRNA) or non-coding (rRNA and tRNA) functions, has 
recently been associated with the occurrence of several human 
degenerative diseases (125). Findings pointing to a previously 
overlooked “quality control” function for APE1 on oxidized RNA 
are therefore surprising and open interesting perspectives to our 
comprehension of cellular biology.
Redox Signaling and APe1/Ref in Stem 
Cell Biology
More than a decade of research has indicated the relevance of 
oxidative stress and, more recently, of redox signaling in stem 
cell biology. In this regard, of particular relevance is the dem-
onstration of both: hypoxia as a common theme of stem cell 
niches (126, 127), and the modulation of stem cell self-renewal, 
differentiation and apoptosis via a “ROS rheostat” (128). These 
two factors are intertwined, since the prevailing hypothesis is that 
hypoxia stabilizes HIF 1α, a transcription factor that coordinates 
the adaptation to low oxygen tension, favoring glycolytic over 
an oxidative metabolism and promoting a quiescent, primitive 
phenotype (129). Conversely, mitochondrial activity and ROS 
levels increase as stem cells differentiate (129, 130). These find-
ings support a role for redox signaling in regulating stem cell 
differentiation processes.
In this regard, it is emerging that ATM kinase regulates stem 
cell quiescence, protecting them from stress (131). This protein, 
that is not only activated by double strand DNA breaks, but also 
by hypoxia and oxidative stress, reduces ROS production, pos-
sibly by inhibiting mTOR (thus stimulating autophagy) via either 
the AMP kinase/tuberous sclerosis complex 2 axis or the HIF1 
α one (132–134). Moreover, an ATM-mediated phosphorylation 
of BH3-interacting domain death agonist (BID) can regulate 
mitochondrial ROS production and promote hematopoietic stem 
cell activation (131).
A similar role in stem cell integrity is played by p53. Consistently 
with its role in stem cell homeostasis, p53 can be stabilized by 
hypoxia, and its transcriptional activity can be modulated in a 
redox-dependent fashion (135, 136). Specifically, under steady 
state (or low stress) conditions, p53 promotes stem cell quiescence 
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over self-renewal and provides protection against oxidative 
stress (e.g., inducing the expression of glutathione peroxidase or 
SOD2), while following acute genotoxic stress, it may be activated 
(e.g., via ATM), promoting cell cycle arrest, DNA repair, or 
apoptosis (136, 137).
APE1 deserves a special mention in our discussion. Indeed, 
it has been demonstrated that APE1 is more involved in regulat-
ing p53 basal levels, than in modulating the activation of p53 in 
response to DNA damage (138). Consistently, it has been shown 
that: APE/Ref-1 is expressed in undifferentiated embryonic and 
adult stem cells (i.e., primitive cells isolated from bone marrow, 
heart, adipose tissue, and dental papilla), it protects them from 
oxidative stress, and, in some cases, it was shown to prevent 
their differentiation (130, 139–141). Conversely, it has been 
shown that senescence of mesenchymal stem cell is associated 
with a decreased expression of APE1 (even in the presence of 
high intracellular ROS levels), while the forced expression of 
APE1 was sufficient to rescue the senescent phenotype (142). 
In line, the forced expression of APE1 in Sca-1-positive cardiac 
progenitors is able to increase their apoptosis resistance and to 
improve their potential to promote myocardial infarction repair 
(143). However, APE1 is also involved in the differentiation pro-
cess of stem cells toward the cardiac, neural and hemangioblast 
phenotype, being upregulated by the increased intracellular ROS 
levels that characterize the differentiation processes. Intriguingly, 
the redox function of APE1 can enhance, repress or direct stem 
cell differentiation toward specific cell types (e.g., neurons and 
cardiomyocytes) (130, 139, 140).
ReDOX SiGNALiNG iN CARDiOvASCULAR 
DiSeASe AND HeART FAiLURe
As anticipated, redox signaling plays a relevant role in the car-
diovascular system too. In line, hypoxic cardiac stem cell niches 
have been identified in vivo by independent groups (144, 145). 
Kocabas et  al. showed that the epicardium and subepicardium 
are the cardiac regions with the lowest vascular density, where 
HIF1α expressing cells are localized. This latter transcription 
factor would promote a glycolytic metabolism and modulate the 
differentiation of primitive cardiac cells (126). With an alternative 
approach that employed the hypoxic probe pimonidazole, Sanada 
et  al. showed the coexistence of normoxic and hypoxic niches 
containing c-Kit+ cells in adult mouse hearts. Intriguingly, they 
also demonstrated that aging is associated with an increased 
frequency of hypoxic niches containing quiescent and senescent 
stem cells (145). However, according to recent reports, the in vitro 
expansion of c-Kit+ cells in an hypoxic environment (0.5% O2) 
keeps cardiac stem cells more quiescent, reducing their rate of 
cell senescence, with respect to standard cultures kept at room 
air (21% O2) (146).
Concerning cell differentiation, it has been shown that differ-
ent stimuli (e.g., electric field stimulation, PI3-kinase signaling) 
can increase cardiomyocyte differentiation of pluripotent cells by 
increasing intracellular ROS (147, 148). In this process, NOX4 is 
considered to be crucial, promoting the nuclear translocation of 
MEF2C in a p38MAPK-dependent fashion (144). However, the 
level of ROS must be strictly controlled, since, when excessively 
high, they may inhibit cardiomyocyte differentiation, too (144, 149). 
Consistently, it has been also shown that the modulation of intra-
cellular ROS, paralleling mitochondrial maturation and closure 
of the mitochondrial permeability transition pore, promotes the 
differentiation of embryonic cardiomyocytes (150). Intriguingly, 
while undifferentiated pluripotent cells are characterized by a 
highly unsaturated metabolome, oxidized metabolites (e.g., acyl-
carnitines) promote cardiomyocyte differentiation (151).
Regarding redox signaling in differentiated cells, a peculiar 
place is occupied by endothelial cells (ECs), whose fate is 
regulated by redox sensitive molecules (that include the tran-
scription factors forkhead box O -FoxO-, Nrf2 and HIF, as 
well as AMPK, PTEN, VEGFR, and eNOS) [reviewed in Ref. 
(152)]. Being at the interface with blood, EC are exposed to 
oxygen, metabolites, and mechanical deformation (i.e., shear 
stress) that may perturb their redox balance. Furthermore, EC 
play crucial roles in cardiovascular homeostasis through the 
release of NO• (which is a labile free radical itself). Therefore, 
although redox signaling is vital for EC, they are in contact 
with exogenous sources of oxidative stress toward which they 
must be protected by means of an antioxidant reserve. In line, 
cardiovascular risk factors (e.g., hyperglycemia, smoking) are 
characterized by their ability to increase ROS generation and to 
decrease endothelial NO• production (153). Going back to redox 
signaling in vascular cells, it has been shown that NOX1, 2, 4, and 
5 are expressed in EC (60), where they exert important physi-
ological roles. However, in pathologic conditions, the induction 
of endothelial NOX increases intracellular ROS levels, triggering 
the further production of free radicals from other sources, such 
as xanthine oxidase and endothelial nitric oxide synthase (154). 
Hyperglycemia, for example, can increase the expression of 
NOX1 in human aortic ECs, while inhibition of NOX1 in diabetic 
apolipoprotein-E (ApoE) deficient mice reduces atherosclerosis 
development (155). Hyperlipidemia too may stimulate ROS 
production by NOX. Accordingly, remnant lipoprotein particles 
or oxidized LDL upregulate NOX2 expression and increment 
ROS production (156, 157), while NOX2−/− ApoE−/− double 
knockout mice are protected against endothelial dysfunction 
and development of atherosclerotic lesions in descending aorta 
(158). Concerning hypertension, vascular NOX are activated by 
different pro-hypertensive factors. Among these, angiotensin II 
(AngII) increases NOX2 expression and function, while deletion 
of NOX1 and NOX2 in hypertensive mouse models is protective 
(159, 160). Intriguingly, although patients carrying hereditary 
deficiency of NOX2 are affected by chronic granulomatous 
disease, they also show increased flow-mediated arterial dila-
tion and increased NO bioavailability (161). Conversely, NOX4 
has been shown to exert protective effects on atherosclerosis 
development, in mouse models (162). The discordant behavior 
of NOX4 with respect to NOX1 and 2 has been attributed to the 
unique features of this enzyme, since it is constitutively active 
and produces mainly H2O2 (162). Moreover, NOX4 is induced by 
hypoxia and can stimulate angiogenesis activating eNOS(163). 
However, experimental evidence indicates that NOX4 may be 
involved in plaque instability too. Specifically, authors observed 
that, while during the early phases of plaque formation NOX1 
was induced, during the late phases, NOX4 prevailed (164). 
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Concerning vascular smooth muscle cells (SMCs), they express 
NOX4, together with NOX1 and 5 (153). The latter has been 
identified only recently and its characterization has been 
hampered by the absence of an ortholog in mice (62). NOX5 
is activated by thrombin, PDGF, AngII, and endothelin 1 and 
regulates SMC proliferation and migration, processes that are 
critically involved in atherosclerosis (62). Importantly, NOX5 
levels are increased, both in EC and SMC, in coronary artery 
disease (165). However, at present its pathophysiological role is 
still unclear (166). Concerning the involvement of senescence 
processes in the development of atherosclerosis, it has been 
recently demonstrated that senescent foam cells, ECs, and 
SMCs can be identified in advanced atherosclerotic plaques. 
Furthermore, the selective removal of senescent cells, by means 
of an inducible suicide gene, significantly reduces the formation 
of atherosclerotic lesions in atherosclerosis-prone Ldlr−/− mice 
(167). Important stressors with a relevant role in atherosclerosis 
(e.g., AngII, advanced glycation end products -AGE-, inflam-
matory molecules, and NOX4 activation) are known inducers 
of vascular cell senescence (164, 168). Moreover, cell senescence 
activates a vicious cycle characterized by a nucleus to mito-
chondria cross talk that can eventually perturb mitochondrial 
dynamics and reinforce cellular senescence (169). Furthermore, 
dysfunctional mitochondria may activate the NLRP3 inflamma-
some, spreading vascular cell senescence paracrinally (170).
Redox signaling is a known mediator of cardiac adaptation 
to different physiological and pathological stimuli, that act both 
in the acute adaptation to damage and in cardiac remodeling 
(171). The major oxidant sources in myocytes are, similarly to 
vascular cells, NOX, xanthine oxidase, uncoupled NOS, and 
mitochondria (including MAO) (171–173). Both NOX2 and 
4 can be found in cardiomyocytes. However, the first one is 
localized at the plasma membrane and in T tubules and requires 
mechanical or agonist stimulation (i.e., G-protein coupled 
receptor agonists, cytokines and growth factors) to be activated 
(174). Conversely, NOX4 is localized in intracellular membranes 
(i.e., the ER and mitochondria), is constitutively active, and is 
regulated mainly at a transcriptional level (174). NOX2 gener-
ated ROS are causally involved in the development of AngII-
induced hypertrophy(175), LPS-induced myocardial depression 
(176), adverse remodeling after myocardial infarction (177), 
and in alcohol-related cardiomyopathy (178). Contrariwise, 
NOX4 expression seems to be protective in cardiac overload, 
by increasing capillary density (in a HIF1α-dependent fashion), 
thus protecting against contractile dysfunction and cardiac dila-
tion (179). The positive effects of NOX4 expression include the 
induction of Nrf2 expression (180), the promotion of autophagy 
via the PERK/eIF2α/ATF4 pathway (181), and the enhancement 
of fatty acid oxidation (182). However, according to other reports, 
chronic and high activation of NOX4 exerts negative effects fol-
lowing pressure overload (183) or phenylephrine stimulation, 
by promoting the exclusion of histone deacetylase 4 (HDAC4) 
from the nucleus, thus stimulating cardiac hypertrophy (183). 
Antioxidant systems too are involved in hypertrophy, as shown 
in mice overexpressing either TRX1 or its dominant negative 
form (184). The mechanism of TRX1-mediated cardioprotection 
involves the transnytrosilation of ≈40 target proteins, including 
chaperones, metabolic-, structural-, redox-, and ribosomal-
proteins and translation regulators (88). Furthermore, TRX1 
can protect against hypertrophy in a redox-dependent fashion 
by regulating the nucleocytoplasmic shuttling of HDAC4 (185). 
In line, several transcription factors that are involved in cardiac 
remodeling (including GATA4, MEF2, NFAT, SRF, and NFκB) are 
under the control of redox sensitive mechanisms. For example, 
MEF2 and NFAT are inhibited by HDAC4 (185, 186), GATA4 is 
activated by ROS via RhoA/ROCK and MEK/ERK (187), SRF is 
activated via MICAL-2/MRTF-A in a redox-dependent fashion, 
and NFκB can be activated via APE/Ref (114). Intriguingly, 
pathways linked to physiological hypertrophy too, such as the 
PI3K/Akt one, can be regulated in a redox-dependent fashion (in 
this specific case by PTEN) (188). Finally, myocyte contractil-
ity, calcium dynamics, and excitation contraction coupling too 
can be modulated by redox sensitive molecules, such as PKA, 
CaMKII, RyR2, phospholamban, and ion channels (e.g., L-type 
calcium channels) (174).
A special mention deserves the involvement of APE1 in 
cardiovascular pathophysiology. Specifically, APE1 reduces 
apoptosis in ECs exposed to hypoxia and TNFα via NFκB-
dependent and -independent mechanisms (189). Moreover, APE1 
hemizygous mice are characterized by impaired endothelium-
dependent vasorelaxation, reduced NO levels and hypertension. 
In fact, experimental evidence indicates that APE1 modulates Akt 
signaling and eNOS function via H-RAS (190). Moreover, E3330, 
a pharmacologic inhibitor of the redox function of APE1, impairs 
both the growth of tumor associated ECs and the differentiation 
of bone marrow derived cells into CD31+ expressing cells. These 
effects were mediated by the modulation of both H-RAS levels 
and of the DNA binding activity of HIF1α (191). Concerning 
atherosclerosis, it was shown that oxidative DNA damage markers 
and APE1 levels are increased in human atherosclerotic plaques 
(192). Elevated level of APE1 was also found in the serum of 
patients affected by coronary artery disease and were further 
incremented in the presence of myocardial infarction (193). This 
finding may be considered a compensatory mechanism, since 
it was also shown that APE1 gene transfer exerts a protective 
effect on atherosclerosis development, reducing SMC migra-
tion and neointima formation (194). A further protective effect 
of APE1 has been shown in ischemic preconditioning, where 
the nuclear accumulation of APE1 mediates cardioprotection 
(195). Similarly, APE1 was able to protect cardiomyocyte from 
death induced by miconazole, a cardiotoxic drug able to increase 
intracellular ROS levels (196). Intriguingly, the expression of exo-
3 (the Caenorhabditis elegans ortholog of APE1) declines with 
aging, while reduced levels of exo-3 shorten the nematode lifespan 
(197). Although a decline in the induction of APE1 in response 
to oxidative stress was observed in the brain of aged rats (198), no 
data have been collected on the role of APE1 cardiovascular aging.
Finally, it is well recognized that the cardiac metabolism is 
altered during the development of cardiac pathology. Specifically, 
a reduction of the myocardial energy reserve (i.e., phospho-
creatine/ATP ratio), an increase of the glucose uptake (and a 
decrease of the fatty acid uptake in overt heart failure), and, most 
importantly, an activation of the pentose phosphate pathway 
(PPP) characterize cardiac pathology and heart failure (199). 
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Although the PPP is a source of NADPH and may be considered 
as a compensatory mechanism that is in place in heart failure, 
recent data suggest that an excessively active PPP may feed NOX 
enzymes and uncoupled nitric oxide synthase, paradoxically 
increasing oxidative stress (200). Conversely, Katare et  al. have 
recently demonstrated that diabetes impairs the PPP and acceler-
ates the dysfunction, senescence, and death of cardiac resident 
stem cells. Importantly, these alterations may be reversed by 
boosting the PPP (17, 201).
CONCLUSiON AND PeRSPeCTiveS
Reactive oxygen species have a dual nature; they exert fun-
damental roles in signal transduction and in many biological 
processes, with a level of complexity that has been only partially 
delineated. However, they may exert harmful effects too, lead-
ing to cell death and senescence. In this regard, the emerging 
knowledge is that redox signaling is tightly regulated and com-
partmentalized, while oxidative stress emerges from the loss of 
this highly controlled architecture. Importantly, redox signaling 
is a crucial regulator of stem cell quiescence, self-renewal, and 
differentiation. Conversely, loss of controlled redox signaling 
(oxidative stress) can obliterate stem cell function and promote 
cell senescence of stem and differentiated cells, two conditions 
that have been associated with the progressive loss of tissue 
renewal and reparative reserve that characterize aging. Cardiac 
stem cells are not immune from these pathological processes, 
becoming dysfunctional and unable to effectively repair cardiac 
damage with organism aging and pathology. mTOR signaling, 
which associates with cardiac stem cell senescence, may affect 
redox signaling at multiple levels, overloading the ER, and inhib-
iting both lysosomal function and autophagy. Therefore, inno-
vative interventions aimed at restoring proper redox signaling 
in primitive cells have the potential to reverse or attenuate 
age-associated stem cell dysfunction. In this regard, although 
the functional manipulation of the multifunctional protein 
APE/Ref-1 in cardiac stem cells has been only recently experi-
mented, it is a promising intervention, that deserves a deeper 
investigation.
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